Overview

A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia

Status:
RECRUITING

Trial end date:
2030-12-31

Target enrollment:

Participant gender:

Summary

To find the recommended dose of ziftomenib in combination with gemtuzumab ozogamicin and venetoclax that can be given to pediatric participants who have relapsed or refractory AML or MPAL.

Phase:

PHASE1

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborator:

Kura Oncology, Inc.

Treatments:

Gemtuzumab
venetoclax